[HT-11] Hot Topics 11
An update on diagnostic and prognostic biomarkers in Parkinson's disesae

[HT-11-4] Pathological biomarker

^○Renpei Sengoku (Departments of Neurology and Neuropathology, Tokyo Metropolitan Geriatric Hospital, Japan)

Biomarkers related to the diagnosis and progression of Parkinson's disease are significant for early diagnosis including prodromal stage, prognosis, and development of novel therapies. Even now, there are excellent biomarkers, and although diagnostic criteria for the prodromal stage have been proposed, improvement in diagnostic sensitivity and specificity is inevitable. Based on such a background, recent advances in visualization technology using MRI and nuclear medicine, a more in-depth understanding of the effects of gut microbiota on the pathology, advances in blood biomarker measurement technology such as α-synuclein, and skin pathology are something amazing. In this session, symposists who are specialists in each field will provide the latest information and knowledge. We hope young researchers will envision the direction and potential of future research and encourage their research minds.

Renpei Sengoku, MD, PhD, is at present the director of Department of Neurology Tokyo Metropolitan Geriatric Hospital. He graduated from the Jikei University School of Medicine in 1999 and became an attending neurologist in Jikei University Hospital. He became an assistant professor of Department of Neurology, Jikei University School of Medicine at 2012. He received the Moore Award from the American Association of Neuropathologists at 2008 and the best research award from the Japan Foundation for Aging and Health at 2009. His major research interests are directed at the clarifying of the path of progression of Parkinson's disease. He is a member of the American Association of Neuropathologists and the Movement Disorder Society.